To the editor: The effect of low-molecular-weight heparin in cancer patients: The mirror image of survival?

Blood

Volumn 124, Issue 1, 2014, Pages 155-156

  Barni, Sandro ^a   Bonizzoni, Erminio ^b   Verso, Melina ^c   Gussoni, Gualberto ^d   Petrelli, Fausto ^a   Perrone, Tania ^e   Agnelli, Giancarlo ^c  

^a TREVIGLIO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d FADOI Foundation Italian Scientific Society of Internal Medicine   (Italy)

^e Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; ANTICOAGULANT AGENT;

ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER SURVIVAL; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MORTALITY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NADROPARIN; NEOPLASMS;

EID: 84904005559     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-561761     Document Type: Letter

References (3)

1. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007;5(4): 729-737. (Pubitemid 46563571)
2. Nagy Z, Turcsik V, Blaskó G. The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009;15(4):689-692.
3. Agnelli G, Gussoni G, Bianchini C, et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10):943-949.